All In Biotech

Drug Trial Radar · NCT07766005

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Oct 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Spyre Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • SPY072Drug

    Solution for SC injection

  • PlaceboDrug

    Matching placebo for SC injection

  • bimekizumabDrug

    Advanced standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Week 16

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 117

    Birmingham, Alabama · Not yet recruiting

  • Site 119

    Rogers, Arkansas · Not yet recruiting

  • Site 111

    Irvine, California · Recruiting

  • Site 113

    Coral Gables, Florida · Not yet recruiting

  • Site 115

    Atlanta, Georgia · Recruiting

  • Site 101

    Indianapolis, Indiana · Recruiting

  • Site 100

    Bowling Green, Kentucky · Recruiting

  • Site 116

    Owensboro, Kentucky · Recruiting

  • Site 108

    Baton Rouge, Louisiana · Recruiting

  • Site 103

    Boston, Massachusetts · Not yet recruiting

  • Site 112

    Boston, Massachusetts · Not yet recruiting

  • Site 127

    Detroit, Michigan · Not yet recruiting

  • Site 120

    Las Vegas, Nevada · Not yet recruiting

  • Site 126

    Las Vegas, Nevada · Not yet recruiting

  • Site 102

    New York, New York · Recruiting

  • Site 104

    The Bronx, New York · Recruiting

  • Site 124

    Durham, North Carolina · Not yet recruiting

  • Site 122

    Oklahoma City, Oklahoma · Not yet recruiting

  • Site 109

    Mt. Pleasant, South Carolina · Recruiting

  • Site 125

    Nashville, Tennessee · Recruiting

  • Site 118

    Smyrna, Tennessee · Recruiting

  • Site 114

    Prosper, Texas · Recruiting

  • Site 107

    Tyler, Texas · Recruiting

  • Site 121

    Tyler, Texas · Recruiting

  • Site 123

    Murray, Utah · Not yet recruiting

  • Site 106

    Mill Creek, Washington · Recruiting

  • Site 163

    Edmonton, Alberta, Canada · Not yet recruiting

  • Site 165

    Surrey, British Columbia, Canada · Not yet recruiting

  • Site 164

    Winnipeg, Manitoba, Canada · Not yet recruiting

  • Site 160

    Barrie, Ontario, Canada · Not yet recruiting

  • Site 167

    Markham, Ontario, Canada · Not yet recruiting

  • Site 162

    Richmond Hill, Ontario, Canada · Not yet recruiting

  • Site 166

    Québec, Quebec, Canada · Not yet recruiting

  • Site 161

    Saskatoon, Saskatchewan, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.